| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/02/2008 | CN101209348A Elastic nano vesicle carrier and preparation and application thereof |
| 07/02/2008 | CN101209347A Pharmaceutical compositions of fibrinolytic agent |
| 07/02/2008 | CN101209241A Method for preparing medicine targeted controlled-release nano eyedrop |
| 07/02/2008 | CN100398154C Remedies for psychoneurosis |
| 07/02/2008 | CN100398153C Combined pharmaceutical application of antiangiogenic drugs and photosensitizers |
| 07/02/2008 | CN100398106C Use of nk-1 receptor antagonists against benign prostatic hyperplasia |
| 07/02/2008 | CN100398104C Medicament comprising combination of antithrombotic agent with pyrazolone derivative |
| 07/02/2008 | CN100398103C Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance |
| 07/02/2008 | CN100398094C Formoterol superfine formulation |
| 07/01/2008 | US7395112 Method and apparatus for treating tumors using low strength electric fields |
| 07/01/2008 | US7393957 Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments |
| 07/01/2008 | US7393944 Lymphocytes; transcription factors; interferons |
| 07/01/2008 | US7393932 Endothelial cell expression patterns |
| 07/01/2008 | US7393875 Reducing islet amyloid polypeptide (IAPP) associated deposit; type II diabetes |
| 07/01/2008 | US7393872 Sodium channel blocker compositions and the use thereof |
| 07/01/2008 | US7393862 Immunomodulators; chemotherapy, radiation therapy, hormonal therapy, biological therapy, immunotherapy |
| 07/01/2008 | US7393857 Use of 5-HT3 receptor antagonists for treating musculoskeletal diseases |
| 07/01/2008 | US7393851 Azaindole derivatives as inhibitors of p38 kinase |
| 07/01/2008 | US7393837 Method for treating metabolic bone disease such as osteomalacia and osteoporosis in a patient by administering a compound that modulates phosphate regulating endopeptidase homolog (PEX) expression and/or PEX enzymatic activity |
| 07/01/2008 | US7393825 Restoring balance in vascular tone without systemic effect in normal vasculature; administration of minimal amounts of nitric oxide donors and/or guanyl cyclase activators |
| 07/01/2008 | US7393655 Nucleotide sequences coding cyclic peptide receptor for use in identifying modulators for treatment of pituitary hormone, epinephrine release, gastrointestinal, cardiovascular, electrolyte balance, hypertensive, diabetic and respiratory system disorder |
| 07/01/2008 | US7393545 Lipstatin derivative—soluble fiber tablets |
| 07/01/2008 | US7393544 Microstructures containing a drug and a suspension medium that permeates into the permeable microstructures; density variations between suspended particles and medium are minimized and attractive forces between microstructures are attenuated, resulting in settling and flocculation resistance |
| 07/01/2008 | US7393541 Mycobacterial vaccine |
| 07/01/2008 | US7393540 Therapeutic peptide for prevention of microorganismal infections; enzyme inhibitors; RNA inteference; antisense agents |
| 07/01/2008 | US7393539 Therapeutic agent for prevention and treatment of bacterial infection; bactericides; genetic vaccines; immunotherapy |
| 07/01/2008 | US7393478 Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| 06/26/2008 | WO2008076278A2 Methods of cancer treatment with igf1r inhibitors |
| 06/26/2008 | WO2008076143A1 Combination of igfr inhibitor and anti-cancer agent |
| 06/26/2008 | WO2008075741A1 Therapeutic agent and prophylactic agent for diabetes |
| 06/26/2008 | WO2008075713A1 Marker for diagnosis of cancer, and target molecule for therapy |
| 06/26/2008 | WO2008075706A1 Therapeutic agent for interstitial pneumonia |
| 06/26/2008 | WO2008075149A2 Ophthalmic compositions of parasympathetic stimulants and anti-inflammatories for use in the treatment of presbyopia |
| 06/26/2008 | WO2008075042A1 Combination comprising cndac (2'-cyano-2'-deoxy-n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosine) and a cytotoxic agent |
| 06/26/2008 | WO2008074975A1 New combination for use in the treatment of inflammatory disorders |
| 06/26/2008 | WO2008074935A2 Biologically active compositions, methods for producing the same and biological applications |
| 06/26/2008 | WO2008074572A1 Use of tri-substituted glycerol compounds for the treatment of hematological malignancies |
| 06/26/2008 | WO2008056391A3 Composition for a pharmaceutical treatment based on triethyl citrate and adapalene |
| 06/26/2008 | WO2008041514A9 Radiation sensitizer or anti-cancer chemotherapy sensitizer |
| 06/26/2008 | WO2008027445A3 Combination with bis(thiohydrazide amides) for treating cancer |
| 06/26/2008 | WO2008016378A3 Methods to treat and/or prevent radiation- and/or chemical-induced toxicity in non-malignant tissue |
| 06/26/2008 | WO2008006051A3 Bicyclic heteroaryl inhibitors of pde4 |
| 06/26/2008 | WO2008006050A3 Bicyclic heteroaryl inhibitors of pde4 |
| 06/26/2008 | US20080153926 Methods and compositions for modulating mitochondrial alderhyde dehydrogenase-2 |
| 06/26/2008 | US20080153921 Amphipathic, lipophilic anti-oxidants, made into potent abzyme inhibitors by increasing solubility in aqueous solvents with lactoproteins; test solublized carotenoids, polyphenols, flavonoids, isoflavones, curcuminoids, ceramides to identify, obtain a composition which inhibits lipid oxidising abzymes |
| 06/26/2008 | US20080153842 Synergistic mixture of a thiazolecarboxamide derivative, especially N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, and an antiproliferative cytotoxic agent such as paclitaxel, procarbazine, mitoxantrone or an epidophyllotoxin |
| 06/26/2008 | US20080153820 pharmaceutically acceptable salt thereof or prodrug thereof, and the use thereof in therapy and in the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A2A receptors, may be beneficial, |
| 06/26/2008 | US20080153807 fused 1,2,4-triazoles for modulating the activity of 11 beta -hydroxysteroid dehydrogenase type 1 (11 beta HSD1) and the use of these compounds as pharmaceutical compositions has been described. Also a novel class of fused 1,2,4-triazoles, their use in therapy, pharmaceutical compositions |
| 06/26/2008 | US20080153766 Non-insulin dependent diabetes mellitus; lowers hepatic fatty degeneration; improving liver function by reducing alanine transaminase and aspartate transaminase levels |
| 06/26/2008 | US20080153107 Isolated PGE synthase, provided from encoding nucleic acid. Methods of production and use. Assays for modulators, especially inhibitors, of PGE synthase activity. |
| 06/26/2008 | US20080152726 Using polyunsaturated fatty acid and agent which adjust methionine metabolism such as vitamin b6, b12, folic acid; Parkinson's and Huntington's disease; antiepileptic agents; schizophrenia; antiepileptic agents; sleep disorders; antidepressants |
| 06/26/2008 | US20080152707 Solubilized CoQ-10 and Carnitine |
| 06/26/2008 | US20080152641 Inhibitors of Siderophore Biosynthesis in Fungi |
| 06/26/2008 | US20080152597 Dermal penetration enhancers and drug delivery systems involving the same |
| 06/26/2008 | US20080152589 Diagnostics and Therapeutics of Neurological Disease |
| 06/26/2008 | US20080149097 Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disordersB |
| 06/26/2008 | CA2673040A1 Use of tri-substituted glycerol compounds for the treatment of hematological malignancies |
| 06/26/2008 | CA2672985A1 Ophthalmic compositions of parasympathetic stimulants and anti-inflammatories for use in the treatment of presbyopia |
| 06/26/2008 | CA2672976A1 New combination for use in the treatment of inflammatory disorders |
| 06/26/2008 | CA2672828A1 Methods of treatment |
| 06/26/2008 | CA2672270A1 Treatments of therapy resistant diseases and drug combinations for treating the same |
| 06/26/2008 | CA2671668A1 Therapeutic composition for interstitial pheumonia |
| 06/25/2008 | EP1935978A1 Method of controlling decomposition of protein by tetracycline antibiotic |
| 06/25/2008 | EP1935899A1 Nucleotide and protein sequence of mammastatin and methods of use |
| 06/25/2008 | EP1935887A1 Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands |
| 06/25/2008 | EP1935442A2 Implantable apparatus for administering a therapeutic agent |
| 06/25/2008 | EP1935432A1 Medical agent containing insulin resistance improving agent |
| 06/25/2008 | EP1935427A2 Methods for treating rheumatoid diseases using a soluble CTLA4 mutant molecule |
| 06/25/2008 | EP1935423A2 Composition for treating and/or prophylaxis of tumors of the breast |
| 06/25/2008 | EP1935416A2 Use of (Z)-2-cyano-3-Hydroxy-but-2-enoic acid-(4'-trifluorromethylphenyl)-amide for treating multiple sclerosis |
| 06/25/2008 | EP1935407A1 Low viscosity liquid dosage forms |
| 06/25/2008 | EP1935244A1 Animal model of schizophrenia |
| 06/25/2008 | EP1933851A1 Vitamin b-12 compositions |
| 06/25/2008 | EP1933818A1 Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels |
| 06/25/2008 | EP1718336B1 Novel combination of anticholinergic and beta mimetics for the treatment of respiratory diseases |
| 06/25/2008 | EP1684806B1 Compositions comprising l-type calcium channel blockers and cholinesterase inhibitors |
| 06/25/2008 | EP1572181B1 Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor and the use of said composition for treating bladder dysfunction |
| 06/25/2008 | EP1534313A4 Ophthalmologic irrigation solutions and method |
| 06/25/2008 | EP1395604B1 Novel anti inflammatory 17.alpha.-heterocyclic-esters of 17.beta.-carbothioate androstane derivatives |
| 06/25/2008 | EP1377164B1 Erythropoietin ameliorates chemotherapy-induced toxicity in vivo |
| 06/25/2008 | EP1351683B1 Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser |
| 06/25/2008 | EP1328271B1 Treatment of neurological and neuropsychological disorders |
| 06/25/2008 | EP1261320B1 Micellar pharmaceutical compositions for buccal and pulmonary application |
| 06/25/2008 | EP1242822B1 Methods of detection of amyloidogenic proteins |
| 06/25/2008 | EP1200127B1 Solutions and methods for inhibition of pain, inflammation and cartilage degradation |
| 06/25/2008 | EP0805859B2 A chemokine receptor able to bind to mcp-1, mip-1 alpha and/or rantes. |
| 06/25/2008 | CN101208107A Quadraphasis continuous graduated estrogen contraceptive |
| 06/25/2008 | CN101208106A Cancer therapeutic agent |
| 06/25/2008 | CN101208077A Novel acetylsalicylic acid formulations |
| 06/25/2008 | CN100397890C Circuit for processing video signal containing information such as closed caption |
| 06/25/2008 | CN100397081C Diagnosing tumorigenicity and determining resistance to the antineoplastic therapy |
| 06/25/2008 | CN100396679C Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase |
| 06/25/2008 | CN100396668C Non-imidazole aryloxypiperidines |
| 06/25/2008 | CN100396344C Applicator for administering preparation of liquid or semi-solid to sufferer mucosa cavity |
| 06/25/2008 | CN100396330C Composition and method for repairing nerve damage and enhancing functional recovery of nerve |
| 06/25/2008 | CN100396283C Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes |
| 06/24/2008 | US7390881 first component is the modified antigenic ectodomain of measles virus hemagglutinin protein, second component fused to first component that binds a surface protein of human immunodeficiency virus; for treating HIV infection and other therapeutic targets against which it is difficult to develop vaccines |
| 06/24/2008 | US7390834 Increased or improved bioavailability of the active agents for oral, intracolonic, pulmonary, and other routes of administrations |
| 06/24/2008 | US7390821 Administering nicotinic acetylcholine receptor antagonist; ocular diseases; monoclonal antibodies |
| 06/24/2008 | US7390817 Combinations of a vanilloid antagonist and an NSAID for the treatment of pain |